MA54468A - Constructions de protéines de fusion pour une maladie associée au complément - Google Patents

Constructions de protéines de fusion pour une maladie associée au complément

Info

Publication number
MA54468A
MA54468A MA054468A MA54468A MA54468A MA 54468 A MA54468 A MA 54468A MA 054468 A MA054468 A MA 054468A MA 54468 A MA54468 A MA 54468A MA 54468 A MA54468 A MA 54468A
Authority
MA
Morocco
Prior art keywords
fusion protein
associated disease
complement associated
protein constructions
constructions
Prior art date
Application number
MA054468A
Other languages
English (en)
French (fr)
Inventor
Justin Andrew Caravella
Michael Steven Curtis
Kelly C Fahnoe
Vernon Michael Holers
Cheng Ran Huang
Susan L Kalled
Ellen Garber Stark
Michael Storek
Frederick Robbins Taylor
Shelia Marie Violette
Original Assignee
Q32 Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Q32 Bio Inc filed Critical Q32 Bio Inc
Publication of MA54468A publication Critical patent/MA54468A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1725—Complement proteins, e.g. anaphylatoxin, C3a or C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA054468A 2018-12-11 2019-12-11 Constructions de protéines de fusion pour une maladie associée au complément MA54468A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862778014P 2018-12-11 2018-12-11

Publications (1)

Publication Number Publication Date
MA54468A true MA54468A (fr) 2022-04-13

Family

ID=71076704

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054468A MA54468A (fr) 2018-12-11 2019-12-11 Constructions de protéines de fusion pour une maladie associée au complément

Country Status (13)

Country Link
US (1) US20240301043A1 (https=)
EP (1) EP3893916A4 (https=)
JP (3) JP7444886B2 (https=)
KR (2) KR20250021629A (https=)
CN (1) CN113660944A (https=)
AU (2) AU2019398214C1 (https=)
IL (1) IL283841A (https=)
MA (1) MA54468A (https=)
MX (1) MX2021006930A (https=)
MY (1) MY209796A (https=)
PH (1) PH12021551398A1 (https=)
SG (1) SG11202106073QA (https=)
WO (1) WO2020123662A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018075783A2 (en) * 2016-10-20 2018-04-26 President And Fellows Of Harvard College In vitro and cell based assays for measuring the activity of botulinum neurotoxins
KR20220019806A (ko) * 2019-06-12 2022-02-17 씨에스엘 이노베이션 피티와이 엘티디 가용성 보체 수용체 1형 변이체 접합체 및 이의 용도
CA3182800A1 (en) 2020-06-14 2021-12-23 Vertex Pharmaceuticals Inc. Complement factor i-related compositions and methods
CN114778418B (zh) * 2022-06-17 2022-09-27 深圳安侣医学科技有限公司 基于显微放大数字图像的血红蛋白分析方法及系统
KR20250057830A (ko) * 2022-08-30 2025-04-29 롱바이오 파마 (수조우) 컴퍼니 리미티드 항-인간 보체 c5 항체 및 이의 융합 단백질
WO2024099320A1 (zh) * 2022-11-10 2024-05-16 天辰生物医药(苏州)有限公司 补体抑制杂合蛋白突变体及其抗体融合蛋白
CN118373913B (zh) * 2024-05-08 2024-11-01 上海百英生物科技股份有限公司 一种抗人Tim-3单克隆抗体及其制备方法
CN118878672A (zh) * 2024-08-01 2024-11-01 河北康立德生物科技有限公司 一种抗曲霉半乳甘露聚糖单克隆抗体、试剂盒及其应用
CN119638823A (zh) * 2024-12-10 2025-03-18 中国医学科学院病原生物学研究所 检测a35r蛋白的单克隆抗体及其应用
CN119431565B (zh) * 2025-01-10 2025-04-08 成都迈科康生物科技有限公司 一种抗hpv16型e6蛋白和e7蛋白的抗体、检测产品及其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
DK0752248T3 (da) 1992-11-13 2000-11-13 Idec Pharma Corp Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig
EP1284752A4 (en) * 2000-04-26 2004-08-18 Elusys Therapeutics Inc BISPECIFIC MOLECULES AND USES THEREOF
AU2002361106B2 (en) * 2001-12-28 2007-06-07 Kyowa Hakko Kirin Co., Ltd. Remedies for arthritis
WO2005063815A2 (en) * 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
WO2006042252A2 (en) * 2004-10-08 2006-04-20 Potentia Pharmeceuticals, Inc. Viral complement control proteins for eye disorders
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
SG186397A1 (en) * 2010-06-22 2013-01-30 Univ Colorado Regents Antibodies to the c3d fragment of complement component 3
US8940490B2 (en) 2010-11-29 2015-01-27 Novelmed Therapeutics, Inc. Neoantibodies for diagnosing tissue injury
JP2015535212A (ja) 2012-08-17 2015-12-10 ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・コロラド、ア・ボデイー・コーポレイト 補体活性化を検出するための組成物および方法
HK1218300A1 (zh) * 2013-01-23 2017-02-10 Musc Foundation For Research Development 基於天然抗體的靶向結構體及其應用
CA2930665A1 (en) * 2013-11-18 2015-05-21 Rubius Therapeutics, Inc. Synthetic membrane-receiver complexes
US10035848B2 (en) * 2014-01-08 2018-07-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibody targeting cell surface deposited complement protein C3d and use thereof
MA39819A (fr) * 2014-04-01 2017-02-08 Rubius Therapeutics Inc Méthodes et compositions d'immunomodulation
WO2015187992A2 (en) * 2014-06-05 2015-12-10 The Regents Of The University Of Colorado, A Body Corporate Map44 polypeptides and constructs based on natural antibodies and uses thereof
CN120988137A (zh) * 2015-01-23 2025-11-21 赛诺菲 抗cd3抗体、抗cd123抗体和与cd3和/或cd123特异性结合的双特异性抗体

Also Published As

Publication number Publication date
AU2019398214A1 (en) 2021-07-01
IL283841A (en) 2021-07-29
JP2022512234A (ja) 2022-02-02
JP2024059791A (ja) 2024-05-01
KR20210148076A (ko) 2021-12-07
CA3123004A1 (en) 2020-06-18
JP2026053563A (ja) 2026-03-25
JP7444886B2 (ja) 2024-03-06
MX2021006930A (es) 2021-11-17
CN113660944A (zh) 2021-11-16
EP3893916A4 (en) 2023-03-29
KR102762828B1 (ko) 2025-02-05
KR20250021629A (ko) 2025-02-13
US20240301043A1 (en) 2024-09-12
EP3893916A2 (en) 2021-10-20
WO2020123662A3 (en) 2020-07-23
WO2020123662A2 (en) 2020-06-18
SG11202106073QA (en) 2021-07-29
MY209796A (en) 2025-08-05
AU2019398214C1 (en) 2024-03-28
AU2024201109A1 (en) 2024-03-14
JP7811315B2 (ja) 2026-02-05
AU2019398214B2 (en) 2023-11-23
PH12021551398A1 (en) 2022-11-07

Similar Documents

Publication Publication Date Title
MA54468A (fr) Constructions de protéines de fusion pour une maladie associée au complément
EP3880814A4 (en) FUSION PROTEIN
EP3930753A4 (en) VARIANT NUCLEIC ACID LIBRARIES FOR GLP1 RECEPTOR
EP3897523A4 (en) MICROCAPSULES MADE FROM PROTEINS
EP3455218A4 (en) C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
MA52655A (fr) Biomarqueurs pour maladie cutanée inflammatoire
EP3701030A4 (en) GENE THERAPIES FOR NEURODEGENERATIVE DISEASES
MA47456A (fr) Anticorps anti-lag3 radiomarqués pour imagerie immuno-pet
EP3749358A4 (en) POLYVALENT PNEUMOCOCCAL POLYSACCHARIDE PROTEIN CONJUGATE COMPOSITION
EP3887396A4 (en) GENE THERAPIES FOR NEURODEGENERATIVE DISEASES
EP3630964A4 (en) THERAPEUTICS FOR GLYCOGEN STORAGE DISEASE OF TYPE III
MA50908A (fr) Formulations de protéines de fusion vegfr-fc
MA50174A (fr) Formules de protéines de fusion vegfr-fc
EP3794151A4 (en) Sec modified strains for improved secretion of recombinant proteins
EP3607963A4 (en) THERAPEUTIC MEDICINAL FOR FIBROUS DISEASE
EP3633372A4 (en) BIOMARKERS FOR ALZHEIMER'S MORBUS
EP3911954A4 (en) BIOMARKERS FOR MODIFICATION OF CNS DISEASES
EP3406255C0 (en) GRAFT MATERIAL FOR THERAPY FOR HEART DISEASES
EP3862012A4 (en) THERAPEUTIC FOR NEURODEGENERATIVE DISEASES
MA51907A (fr) Posologie pour un traitement avec des protéines de fusion il-22 fc
EP3796980A4 (en) NEW THERAPY FOR ALZHEIMER'S DISEASE
EP3634466A4 (en) MONOCATENARY TNF RECEPTOR 2 AGONIST FUSION PROTEINS
EP4190803A4 (en) SIRPa-FC FUSION PROTEIN
IL279782A (en) Methods of producing recombinant proteins
PT3774879T (pt) Variantes de anticorpos c-terminais